GlaxoSmithKline (GSK) announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion and recommends approval of GSK's candidate pandemic (H1N1) adjuvanted vaccine Pandemrix. The indication for the vaccine is for protection against pandemic H1N1 2009 influenza.
The details can be read here.
No comments:
Post a Comment